|
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical research trials and A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD clinical trial. Human subjects often receive the most effective healthcare possible for their A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD  A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
For Condition: Bronchitis, Chronic,Pulmonary Disease, Chronic Obstructive
Status: Completed
Sponsor(s): Abgenix ,
Synopsis: To determine if ABX-IL8 will improve shortness of breath.
Details: Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible. Inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue destruction. Interleukin-8 (IL-8) plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction. Therefore, the highly specific antibody to IL-8 (such as ABX-IL8) may help to reduce mucous production and tissue destruction.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - > 50 years old - > 20 pack-year of smoking - Diagnosed with COPD and chronic bronchitis Exclusion Criteria: - Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, CHF - Require oxygen therapy - Uncontrolled hypertension - HIV or Hepatitis - Recent history of COPD exacerbation - Patients with cancer - Recent history of infection
Total Enrollment: 150
Location and Contact Information:
Abgenix
Fremont, California, 94555
United States
Additional Information:
Study ID Numbers: ABX-0209;
Study Start Date: December 2001
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035828
Other Bronchitis, Chronic Studies:
1. Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD)
2. Effect of Ventilation-Feedback Training on Exercise Performance in COPD
3. A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
4. Study Evaluating the Safety and Efficacy of Infliximab in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Related Studies:
Other Bronchitis, Chronic Clinical Trials
Other California Clinical Trials
Other Fremont Clinical Trials
A blinded study comparing the safety and efficacy of a fully human anti-IL8 monoclonal antibody (ABX-IL8) to placebo in patients with chronic bronchitis and COPD
|
|
|
|
|
|
|
|
